Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine for IOP Spikes after Anti-VEGF Injection
NCT03513172Completed
- Sponsor
- University of Toronto
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
01
Overview
Randomised, single-blind trial of Onreltea (2 arms), sponsored by University of Toronto. Primary endpoint: Change in Post-Injection Intraocular Pressure Spike. Started Dec 2016; status: completed.
02
Drugs
Onreltea
Beyond the preview
Go deeper on NCT03513172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513172.